Merger talks underway between Teva and Barr, Roche and Genentech
Teva plans to acquire Barr for $7.6 billion; Roche plans to take over Genentech at $89 a share
The dog days of summer are usually quiet, but not this year. Merger and acquisition activity is at a high level. Teva announced that it is planning to acquire Barr for $7.6 billion. The deal, if approved, will further strengthen Teva's position as the No. 1 generic drug company in the world. Teva hopes to complete the deal before the end of this year. On another front, Roche, which already owns about a 56% stake in Genentech, reported that it plans to gobble up the rest of the biotech company at $89 a share. Genentech executives were reportedly blindsided by the offer.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
